Using Real-World Data to Predict Clinical and Economic Benefits of a Future Drug Based on its Target Product Profile
Abstract Introduction For a new drug to be developed, the desired properties are described in a target product profile. Objective We propose a framework for using real-world data to measure the disease-specific costs of the current standard of care and then to project the costs of the proposed new p...
Saved in:
Main Authors: | Christoph Gerlinger (Author), Thomas Evers (Author), Jeremy Rassen (Author), Richard Wyss (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet
by: C.M. Montecucco, et al.
Published: (2011) -
Advancing Virtual Bioequivalence for Orally Administered Drug Products: Methodology, Real-World Applications and Future Outlook
by: Sivacharan Kollipara, et al.
Published: (2024) -
Natural Antimicrobials in Dairy Products: Benefits, Challenges, and Future Trends
by: Maria Eduarda Marques Soutelino, et al.
Published: (2024) -
Real world evidence of long-term benefits from allergen-specific immunotherapy (AIT)
by: Guy Scadding
Published: (2022) -
Sharing real-world data for public benefit: a qualitative exploration of stakeholder views and perceptions
by: Susan Baxter, et al.
Published: (2023)